Skip to content

About Us
Pipeline
Publications
Investor Relations
Contact Us

×

About Us
Pipeline
Publications
Investor Relations
Contact Us

Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers

We are a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients

Company

Pipeline
Eblasakimab
Farudodstat
Publications
About Us
Investor Relations
Contact Us

Contact Us

US Office

400 Concar Drive
San Mateo, CA 94402
USA

Singapore Office

3 Temasek Avenue,
Level 18,
Singapore 039190

contact@aslanpharma.com

Social Media

© Copyright ASLAN Pharmaceuticals 2025. All Rights Reserved | Website by Singapore Website Designer

Privacy Policy Terms of Use

Scroll To Top